Printer Friendly


Biopharma: A study conducted by Nature Biotechnology finds that between 2000 and 2003, more than 60 biopharmaceuticals were approved, joining the 84 already authorized in the US and/or the European Union. This means that during the last three years, biopharmaceuticals have made up more than one-quarter of all new drugs approved. Hepatitis, which has infected more than two billion people worldwide, is most frequently targeted by the new medicines; other major targets include diabetes, hemophilia, myocardial infarction and cancer. While biopharma therapies have had an important impact on illness, they have been far from perfect, prompting 15 safety alerts or warnings since 2000. Even so, the study predicts that biopharma medicine will continue to make inroads into other markets, such as veterinary medicine.

Source: Nature Biotechnology
COPYRIGHT 2003 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry Watch
Publication:Instrument Business Outlook
Article Type:Brief Article
Geographic Code:4E
Date:Oct 15, 2003
Previous Article:Aluminum makers flex to meet market challenges.
Next Article:Government.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |